Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00520572 · ClinicalTrials.gov registry record · Phase 2
A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
NCT00520572 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 385 participants.
The verdict
NCT00520572, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
Study Summary
The purpose of this study is to confirm that AZD9056 is effective in treating rheumatoid arthritis with regard to signs and symptoms and to determine what dose is favourable over a 6-month treatment period. Patients will receive background treatment with either Methotrexate or Sulphasalazine
Interventions
- DRUG Placebo
- DRUG Etanercept
- DRUG AZD9056
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00520572
The ClinicalTrials.gov registry entry for NCT00520572 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00520572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00520572 about?
NCT00520572 is a clinical study titled "A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)". The purpose of this study is to confirm that AZD9056 is effective in treating rheumatoid arthritis with regard to signs and symptoms and to determine what dose is favourable over a 6-month treatment period. Patients will receive background treatment with either Methotrexate or Sulphasalazine
What is the current status of trial NCT00520572?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2007-08. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00520572?
The interventions under investigation include: Placebo (DRUG), Etanercept (DRUG), AZD9056 (DRUG).
Who is sponsoring clinical trial NCT00520572?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.